Cite
HARVARD Citation
Passamonti, F. et al. (2022). Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Lancet. 9 (7), pp. e480-e492. [Online].